# US 2021/0330651 A1 · Estrogen receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330651 A1
- Document ID: US20210330651A1
- Status: Published application
- Kind: A1
- Application number: 17/305,369
- Filed: 2021-07-06
- Published: 2021-10-28
- Earliest claimed: 2016-04-01
- Assignees: Recurium IP Holdings, LLC
- Applicants: Recurium IP Holdings, LLC
- Inventors: Peter Qinhua Huang; Deborah Helen Slee; Sayee Gajanan Hegde; Chad Daniel Hopkins; Kevin Duane Bunker; Joseph Robert Pinchman; Rakesh Kumar Sit
- Web page: https://patentgrep.com/patent/US20210330651A1

## CPC

- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 5/30: Oestrogens
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07C 69/732: of unsaturated hydroxy carboxylic acids
- C07C 69/738: Esters of keto-carboxylic acids {or aldehydo-carboxylic acids}
- C07C 69/757: having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety
- C07D 209/10: with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D 471/04: Ortho-condensed systems
- C07D 471/14: Ortho-condensed systems
- C07C 2603/62: containing three- or four-membered rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method of inhibiting the growth of a cell, comprising
identifying a cell having an estrogen receptor alpha that mediates a growth characteristic of the cell; and
contacting the cell with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
X1, Y1 and Z1 are each independently C or N;
with the first proviso that at least one of X1, Y1 and Z1 is N;
with the second proviso that each of X1, Y1 and Z1 is uncharged;
with third proviso that two of the dotted lines indicate double bonds;
with the fourth proviso that the valencies of X1, Y1 and Z1 can be each independently satisfied by attachment to a substituent selected from H and R12;
X2 is O, NH or S;
A1 is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;
R1 is selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted cycloalkenyl(C1-6 alkyl), an optionally substituted aryl(C1-6 alkyl), an optionally substituted heteroaryl(C1-6 alkyl) and an optionally substituted heterocyclyl(C1-6 alkyl);
R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R2 and R3 together with the carbon to which R2 and R3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R4 and R5 together with the carbon to which R4 and R5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
R10 is hydrogen, deuterium, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
R11 is hydrogen or an optionally substituted C1-6 alkyl; and
R12 is hydrogen, halogen, an optionally substituted C1-3 alkyl, an optionally substituted C1-3 haloalkyl or an optionally substituted C1-3 alkoxy;
provided that when R11 is hydrogen or methyl, X1 is NH, Y1 and Z1 are each C, X2 is O, A1 is a phenyl, 2-fluorophenyl, or 2,6-difluorophenyl, both R2 and R3 are methyl or one of R2 and R3 is hydrogen and the other of R2 and R3 is methyl, and R4, R5, R6, R7, R8, R9 and R10 are each hydrogen, then R1 cannot be 2-hydroxyethyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 3-fluoro-2-methylpropyl, 3-hydroxy-2-methylpropyl or 2-fluoro-3-hydroxy-2-methylpropyl.

### Claim at position 3

33-49. (canceled)

### Claim 50 (depends on 32)

The method of claim 32, wherein R11 is hydrogen.

### Claim 51 (depends on 32)

The method of claim 32, wherein A1 is an optionally substituted aryl.

### Claim 52 (depends on 51)

The method of claim 51, wherein A1 is an optionally substituted phenyl.

### Claim 53 (depends on 51)

The method of claim 51, wherein A1 is a substituted phenyl.

### Claim 54 (depends on 51)

The method of claim 51, wherein A1 is an unsubstituted phenyl.

### Claim 55 (depends on 32)

The method of claim 32, wherein A1 is an optionally substituted cycloalkyl.

### Claim 56 (depends on 55)

The method of claim 55, wherein A1 is an optionally substituted bicyclopentyl.

### Claim 57 (depends on 56)

The method of claim 56, wherein A1 is an unsubstituted bicyclopentyl.

### Claim 58 (depends on 32)

The method of claim 32, wherein R1 is selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted heterocyclyl and an optionally substituted heterocyclyl(C1-6 alkyl).

### Claim 59 (depends on 58)

The method of claim 58, wherein R1 is a substituted C1-6 alkyl or a substituted cycloalkyl.

### Claim 60 (depends on 59)

The method of claim 59, wherein the substituted cycloalkyl is substituted with one or more substituents selected from the group consisting of halogen, hydroxy, haloalkyl, an optionally substituted alkyl, an optionally substituted cycloalkyl, a substituted alkoxy, a substituted mono-substituted amine and a substituted di-substituted amine.

### Claim 61 (depends on 59)

The method of claim 59, wherein the substituted alkyl is a C1-6 haloalkyl.

### Claim 62 (depends on 59)

The method of claim 59, wherein the substituted C1-6 alkyl is substituted with one or more substituents selected from the group consisting of halogen, hydroxy, haloalkyl, an optionally substituted cycloalkyl, a substituted alkoxy, a substituted mono-substituted amine and a substituted di-substituted amine.

### Claim 63 (depends on 58)

The method of claim 58, wherein R1 is an optionally substituted C1-6 alkyl selected from the group consisting of C4 alkyl, fluoro(C4 alkyl), and trifluoro(C2 alkyl).

### Claim 64 (depends on 58)

The method of claim 58, wherein R1 is an optionally substituted cycloalkyl selected from the group consisting of unsubstituted cyclobutyl, unsubstituted difluorocyclobutyl, unsubstituted cyclopentyl and unsubstituted bicyclopentyl.

### Claim 65 (depends on 58)

The method of claim 58, wherein R1 is an optionally substituted cycloalkyl(C1-6 alkyl) selected from the group consisting of unsubstituted cyclopropylmethyl, unsubstituted bicyclopentylmethyl, unsubstituted fluorocyclopropylmethyl, unsubstituted fluorocyclobutylmethyl, unsubstituted methoxycyclopropylmethyl, and unsubstituted trifluoromethylcyclopropylmethyl.

### Claim 66 (depends on 58)

The method of claim 58, wherein R1 is an optionally substituted heterocyclyl selected from the group consisting of unsubstituted tetrahydropyranyl, unsubstituted tetrahydrofuranyl, and unsubstituted oxetanyl.

### Claim 67 (depends on 58)

The method of claim 58, wherein R1 is an optionally substituted heterocyclyl(C1-6 alkyl) selected from the group consisting of unsubstituted oxetanylmethyl and unsubstituted fluorooxetanylmethyl.

### Claim 68 (depends on 32)

The method of claim 32, wherein R2 is selected from the group consisting of hydrogen, methyl, fluoromethyl and difluoromethyl.

### Claim 69 (depends on 32)

The method of claim 32, wherein any one or more of each of R2, R3, R4, R5, R6, R7, R8, R9 and R10 is hydrogen.

### Claim 70 (depends on 32)

The method of claim 32, wherein R6 is hydroxy.

### Claim 71 (depends on 32)

The method of claim 32, wherein R7 is selected from the group consisting of halogen, hydroxy, and unsubstituted alkoxy.

### Claim 72 (depends on 71)

The method of claim 71, wherein R7 is fluoro or methoxy.

### Claim 73 (depends on 32)

The method of claim 32, wherein R8 is hydroxy.

### Claim 74 (depends on 32)

The method of claim 32, wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 75 (depends on 32)

The method of claim 32, wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 76 (depends on 32)

The method of claim 32, wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 77 (depends on 32)

The method of claim 32, wherein the compound of Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 78 (depends on 32)

The method of claim 32, provided that when R10 is hydrogen, R11 is hydrogen or methyl, X1 is NH, Y1 and Z1 are each C, A1 is an optionally substituted phenyl, one of R2 and R3 is hydrogen or an optionally substituted C1-6 alkyl and the other of R2 and R3 is an optionally substituted C1-6 alkyl, then R1 cannot be a substituted C1-6 alkyl substituted with one or more substituents selected from the group consisting of halogen and hydroxy.

### Claim 79 (depends on 32)

The method of claim 32, wherein the compound of Formula (I) is a compound of the Formula 11A:
or a pharmaceutically acceptable salt thereof.
